It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis.
The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial’ (ABSTRACT NUMBER: 1444) was presented at the 2020 ACR Convergence, 5-9 November.
Questions
- What are the arguments for and against the treat-to-target (T2T) strategy in the management of axial spondyloarthritis? (0:05)
- Could you tell us a little about the design of the TICOSPA trial? (1:51)
- What were the findings of this study in terms of primary outcomes and safety of the T2T strategy? (2:55)
- What are the implications of these findings for clinical practice? (4:10)
Disclosures: Anna Moltó has acted as a Consultant/Speaker for Abbvie, BMS, Eli Lilly, Novartis, UCB and Gilead.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
